NEW YORK (GenomeWeb News) — Gene Network Sciences said today that it will use its REFSTM software in an alliance with H. Lee Moffitt Cancer Center subsidiary M2Gen to develop cancer diagnostics and therapeutics
GNS will use REFSTM, which stands for reverse engineering and forward simulation, to reverse-engineer computer models from de-identified tumor molecular profiling data provided by Moffitt.
Researchers will use the models to identify genes that cause cancer progression, and the relationships between those genes and endpoints such as recurrence and survival.
The parties will “work together to validate the discoveries and will work with strategic partners to rapidly bring the diagnostics to market,” GNS said in a statement.
Financial terms of the agreement were not disclosed.